lilly glp 1 agonist Eli to seek approval of new GLP-1 weight-loss drug this year Orforglipron, an Oral Small-Molecule GLP-1

82104307), Natural Science Foundation of Hunan Province (No

Participants 1:1 propensity score matched adults with type 2 diabetes newly starting SGLT-2 inhibitors versus DPP-4 inhibitors (n=778 908), GLP-1 receptor agonists versus DPP-4 inhibitors (n=729 820), and SGLT-2 inhibitors versus GLP-1 receptor agonists (n=873 460)

Accessed on March 21, 2025, at PlushCare content is reviewed by MDs, PhDs, NPs, nutritionists, and other healthcare professionals

Mann JFE, Rossing P, Bakris G et al

Underserved populations, including those with food insecurity, disabilities, or poor health, are at even higher risk for cost-related nonadherence